Incidence of hematological malignancies in Europe by morphological subtype: results of the HAEMACARE project

July 28, 2010

BlankBlood First Edition Paper, prepublished online July 27, 2010; DOI

10.1182/blood-2010-05-282632.

Incidence of hematological malignancies in Europe by morphological subtype:

results of the HAEMACARE project

Milena Sant1,*, Allemani1, Carmen Tereanu1, a De Angelis2,

Riccardo Capocaccia2, Otto Visser3, Marcos-Gragera4, Marc Maynadié5,

Arianna Simonetti2, Jean-Michel Lutz6 and Franco Berrino7

1 Department of Preventive and Predictive Medicine, Analytical Epidemiology

Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2 Department

of Cancer Epidemiology, National Centre for Epidemiology, Surveillance and

Health Promotion, Istituto Superiore di Sanita, Rome, Italy; 3 Amsterdam Cancer

Registry, Netherlands; 4 Girona Cancer Registry, Spain; 5 Cote D'Or Cancer

Registry of Haematological Malignancies, EA4184, University of Burgundy, Dijon,

France; 6 Geneva Cancer Registry, Switzerland; 7 Department of Preventive and

Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Fondazione

IRCCS Istituto Nazionale dei Tumori, Milan, Italy

* Corresponding author; email: milena.sant@...

Abstract

Changing definitions and classifications of haematological malignancies (HMs)

complicate incidence comparisons. HAEMACARE classified HMs into groupings

consistent with the latest WHO classification and useful for epidemiologic and

public health purposes. We present crude, age-specific and age-standardised

incidence rates for European HMs according to these groupings, estimated from

66,371 lymphoid malignancies (LMs) and 21,796 myeloid malignancies (MMs)

registered in 2000-2002 by 44 European cancer registries, grouped into 5

regions. Age-standardised incidence rates were 24.5 (per 100,000) for LMs and

7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.62), small B-cell

lymphocytic lymphoma/chronic lymphatic leukaemia (3.79), diffuse B-cell lymphoma

(3.13) and Hodgkin lymphoma (2.41). The commonest MMs were acute myeloid

leukaemia (2.96), other myeloproliferative neoplasms (1.76) and myelodysplastic

syndrome (1.24). Unknown morphology LMs were commonest in Northern Europe

(7.53); unknown morphology MMs were commonest in Southern Europe (0.73). Overall

incidence was lowest in Eastern Europe, and lower in women than men. For most

LMs, incidence was highest in Southern Europe; for MMs incidence was highest in

UK & Ireland. Differences in diagnostic and registration criteria are an

important cause of incidence variation, however different distribution of HM

risk factors also contributes. The quality of population-based HM data needs

further improvement.

Recommended Posts